| Organising, validating and selecting the relevant information is the key to making the right decisions during drug, and other, development. Understanding complex disease pathways by observing the function and interaction of genes (physiogenomics), and discovering new targets and lead candidates has become a major challenge now that massive amounts of information are available through the various high-throughput technologies.This article discusses new tools, including bioinformatics, that overcome existing limitations such as reproducibility, sensitivity and specificity for data analysis, disease space identification, drug development and patient clustering. In the genomic age, the rapid discovery of new therapeutic strategies for multi-factorial diseases relies on the identification and comparison of correlates and cross talks between functional pathways in human and animal models. Understanding these pathways that drive the progression of complex pathologies at cellular and molecular levels, is now perceived as the new challenge of modern physiogenomics.
|